AZD6793 + Placebo

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Inflammatory Diseases

Conditions

Inflammatory Diseases

Trial Timeline

Dec 5, 2022 → Oct 29, 2024

NCT ID

NCT05662033

About AZD6793 + Placebo

AZD6793 + Placebo is a phase 1 stage product being developed by AstraZeneca for Inflammatory Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT05662033. Target conditions include Inflammatory Diseases.

What happened to similar drugs?

10 of 20 similar drugs in Inflammatory Diseases were approved

Approved (10) Terminated (3) Active (10)

✅Infliximab + Infliximab + InfliximabCelltrionApproved

✅fidaxomicinAstellas PharmaApproved

✅RisankizumabAbbVieApproved

✅Human Papillomavirus VaccineMerckApproved

✅BezlotoxumabMerckApproved

✅Celecoxib + Ibuprofen plus OmeprazolePfizerApproved

✅Alemtuzumab infusionSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05662033	Phase 1	Completed	Dec 5, 2022	Oct 29, 2024	Inflammatory Diseases

Competing Products

20 competing products in Inflammatory Diseases

See all competitors

Product	Company	Stage	Hype Score
Infliximab + Infliximab + Infliximab	Celltrion	Approved	50
CT-P13	Celltrion	Phase 3	36
Subcutaneous infliximab CT-P13 Remsima®SC	Celltrion	Pre-clinical	22
Infliximab subcutaneous + Immunosuppressive Agents	Celltrion	Phase 3	47
fidaxomicin	Astellas Pharma	Approved	43
Eribulin + Adriamycin + Cyclophosphamide	Eisai	Phase 2	39
E6007 + E6007 + E6007 + E6007 + E6007 + E6007	Eisai	Phase 1	29
Placebo + MORF-057	Eli Lilly	Phase 2	42
Baricitinib + Baricitinib	Eli Lilly	Phase 2	35
LY3114062 SC + Placebo + LY3114062 IV	Eli Lilly	Phase 1	29
MORF-057 + Placebo	Eli Lilly	Phase 2	39
MORF-057	Eli Lilly	Phase 2	35
LY3009104	Eli Lilly	Phase 1	29
HRF2105 patch + Loxoprofen patch + placebo	Jiangsu Hengrui Medicine	Phase 2	31
Risankizumab	AbbVie	Approved	43
GC012F Injection infusion	AstraZeneca	Phase 1	36
Human Papillomavirus Vaccine	Merck	Approved	43
Pembrolizumab	Merck	Phase 2	31
Gardasil vaccine	Merck	Pre-clinical	26
Bezlotoxumab	Merck	Approved	35